HOME >> BIOLOGY >> NEWS
BioMed Central is pleased to announce the publication of Sydney Brenners autobiography

Today one of the worlds most famous living biologists, Sydney Brenner, publishes his scientific autobiography with BioMed Central (www.biomedcentral.com).

A giant of modern biology, Sydney has contributed enormously to the fields of molecular and developmental biology over the past 50 years. Famously, he identified and named 'messenger RNA', which is crucial for converting the genetic code of DNA into proteins. Later, shifting direction in his research, he pioneered the use of the nematode worm Caenorhabditis elegans as a model organism for developmental biology - an animal that is now the focus of work for over 1000 researchers across the globe.

My Life in Science, as the autobiography is called, offers a unique window into the world of scientific discovery. Sydney vividly takes us through intense discussions with other, world-renowned scientists, the frustration of disappointing experiments and the intense build-up to that 'Eureka!' moment. We follow him from his modest beginnings, living in his fathers shoe shop in South Africa, to the heights as director of the MRC Laboratory of Molecular Biology in Cambridge, England and beyond.

This entertaining account captures the essence of a renowned scientist and captivating raconteur who has achieved something of a cult status within the biomedical community. His sharp wit and withering humour on the subject of the researchers lot appeared for many years in the columns of the journal Current Biology. Now, finally, we have a chance to hear his own story, in his own words.


'"/>

Contact: Gordon Fletcher
gordon@biomedcentral.com
44-20-7323-0323
BioMed Central
25-Jul-2001


Page: 1

Related biology news :

1. BioMed Central to consult funders and librarians over Open Access payment model
2. LA BioMed Medical/Research Briefs, July/August 2004
3. BioMed Central explodes Open Access myths
4. The Scientist and BioMed Central come together to publish high-impact magazine
5. BioMed Central to deposit e-journals with the British Library
6. BioMed Central to consider charging authors for paper submissions
7. Get Research on the move with BioMed Central
8. BioMed Central to launch at microbiology meeting
9. BioMed Central to free scientists and clinical researchers from copyright restrictions
10. USAID, Conservation International & Starbucks launch Conservation Coffee Alliance in Central America
11. Sediments in many Central Valley streams contain toxic levels of pyrethroid pesticides

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... 08, 2020 , ... Overcoming Comparability Issues in Regenerative Medicines ... Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, https://www.fdanews.com/cellandgenetherapy , ... way to complete one? Will the study comply with all FDA requirements? Understanding ...
(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... monoclonal antibody development services, today announced that the company has received ISO9001:2015 ... the pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... (PRWEB) , ... June 30, ... ... expert tissue data insights, today announced that the launch of a new ... along with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is ...
(Date:6/28/2020)... , ... June 25, 2020 , ... ... advance photodynamic therapy for treating cancer, today announced the company has entered a ... Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual ...
(Date:6/23/2020)... ... June 23, 2020 , ... DeCurtis Corporation, the premier provider ... Derek Fournier has been appointed CEO and President. Founder and former CEO, David ... , “DeCurtis Corporation has been on an incredible journey for the last twenty ...
(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... innovative CNS therapies, today announced that it has filed an Investigational New Drug ... Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients with ...
Breaking Biology Technology:
Cached News: